Galapagos NV is a pharmaceutical company based in Belgium with a Medium Risk rating score of 26.7. Specializing in discovering, developing, and commercializing medicines, Galapagos NV focuses on targeting diseases with high unmet needs to improve patients’ lives globally. The company's R&D capabilities include various drug modalities like small molecules and cell therapies, with a portfolio covering programs in immunology, oncology, and other indications. Galapagos NV's first medicine for rheumatoid arthritis and ulcerative colitis is currently available in Europe and Japan, generating a significant amount of revenue from the United States of America. The company places a strong emphasis on ESG principles in its operations.